



(51) International Patent Classification:

C07K 16/24 (2006.01) A61P 25/28 (2006.01)
C07K 16/16 (2006.01) C07K 16/18 (2006.01)

(21) International Application Number:

PCT/US2022/078776

(22) International Filing Date:

27 October 2022 (27.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/273,216 29 October 2021 (29.10.2021) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **CHEDID, Marcio**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **FLEISHER, Adam S.**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **LAN-NAN, Megan Brittany**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **LO, Albert**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

Indianapolis, Indiana 46206-6288 (US). **MINTUN, Mark**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **OBUNGU, Victor H.**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **RAINES, Sarah Elisabeth**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **SIMS, John Randall II**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **SKORA, Andrew Dixon**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **WALSH, Robin Elizabeth**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **WEST, Elizabeth Anne**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **YE, Ming**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **WOOD, Dan L.** et al.; Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

(54) Title: COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34




FIGURE 1

(57) Abstract: The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.

[Continued on next page]

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*